Literature DB >> 3319364

Effect of maturation on drug disposition in pediatric patients.

C F Stewart1, E M Hampton.   

Abstract

Maturational changes in the physiologic processes that govern drug disposition in pediatric patients are described, and evaluation of data from pediatric drug studies is discussed. Gastrointestinal absorption depends on gastric pH, gastric emptying time, intestinal transit time, and gastrointestinal enzymatic activity; the overall effect of age-related alterations in these variables is poorly understood. Maturational changes in the skin affect percutaneous absorption. Distribution of drugs is affected by alterations in vascular perfusion, body composition, tissue binding, and plasma protein binding. For most water-soluble drugs, volume of distribution is increased in neonates. Age-related changes in biotransformation are complex because the rate of development of phase 1 and phase 2 metabolic pathways varies and metabolic pathways may be induced by in utero exposure to inducing agents. For most drugs, biotransformation is decreased in the neonate, increases from one to five years of age, and decreases after puberty to adult values. The kidneys of neonates are inefficient at drug elimination, leading initially to prolonged elimination half-lives of many drugs. Clearance of some drugs may be greater in infants than in older children and adults because of disproportionate development of renal filtration and secretion in relation to reabsorption. Few data on maturational changes in physiologic processes that affect drug disposition are available for any one drug in a specific pediatric population. In the development of research protocols, careful attention should be paid to the design limitations of published studies.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3319364

Source DB:  PubMed          Journal:  Clin Pharm        ISSN: 0278-2677


  28 in total

Review 1.  The interplay between drugs and the kidney in premature neonates.

Authors:  Michiel F Schreuder; Ruud R G Bueters; Karel Allegaert
Journal:  Pediatr Nephrol       Date:  2013-11-12       Impact factor: 3.714

Review 2.  Therapeutic drug monitoring in the neonate and paediatric age group. Problems and clinical pharmacokinetic implications.

Authors:  J T Gilman
Journal:  Clin Pharmacokinet       Date:  1990-07       Impact factor: 6.447

Review 3.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

4.  Effects of light exposure on total parenteral nutrition and its implications in the neonatal population.

Authors:  David S Hoff; Amanda S Michaelson
Journal:  J Pediatr Pharmacol Ther       Date:  2009-07

Review 5.  Drug dosage in children with reduced renal function.

Authors:  Markus Daschner
Journal:  Pediatr Nephrol       Date:  2005-08-23       Impact factor: 3.714

6.  The Population Pharmacokinetics of High-Dose Methotrexate in Infants with Acute Lymphoblastic Leukemia Highlight the Need for Bedside Individualized Dose Adjustment: A Report from the Children's Oncology Group.

Authors:  Ryan J Beechinor; Patrick A Thompson; Michael F Hwang; Ryan C Vargo; Lisa R Bomgaars; Jacqueline G Gerhart; ZoAnn E Dreyer; Daniel Gonzalez
Journal:  Clin Pharmacokinet       Date:  2019-07       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age.

Authors:  Emilio Perucca
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 8.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years.

Authors:  Charles Oo; George Hill; Albert Dorr; Baolian Liu; Samuel Boellner; Penelope Ward
Journal:  Eur J Clin Pharmacol       Date:  2003-08-09       Impact factor: 2.953

Review 10.  Treatment options for the pharmacological therapy of neonatal meningitis.

Authors:  C M Paap; J A Bosso
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.